There is probably no other prescription drug (in the past) that has been more anticipated and welcomed by doctors and patients than Qsymia, a weight loss drug developed by Vivus, Inc. and approved by the U.S. Food and Drug Administration (FDA) in 2012. Qsymia is intended as an adjunct medication to obese and overweight individuals who fail to lose weight despite a healthy calorie-less diet and regular exercise.
The approval of Qsymia came at a time when doctors were in dire need of a new weight loss medication which they could prescribe to more than one-third of American adults suffering from obesity, considering the fact that the last chronic weight management medication was approved way back in 1999. Majority, if not all, of these obesity pills, though, had one common problem: they caused side-effects that were severe enough to make their own manufacturers pull them out of the market, or for the FDA to order them pulled out or not to be distributed in the US market due to the severe harm that they caused (or could cause) in patients.
Some of the serious adverse events that were connected to the use of these pills were permanent liver and/or kidney damage, lung disorder or pulmonary hypertension, heart valve and other heart-related diseases, stroke, depression, suicidal thoughts, and others.
With regard to Qsymia, results of long-term studies conducted on it showed that it was capable of delivering very favorable outcome, which included considerable weight loss, lower blood pressure and cholesterol, reduced cardiac risk factors and improvement in the user’s quality of life. It was, therefore, probably surprising, at least for its manufacturer, to hear about the serious side-effects being reported and linked to its use due to the study’s positive results and its being in the market for only two years.
Qsymia (formerly traded under the name Qnexa), which combines two other FDA-approved drugs, phentermine and topiramate (Topamax) extended-release, has been linked to risks of heart problems, cognitive problems, impaired concentration, birth defect, decrease in mood, changes in kidney function, tingling in fingers/toes (a condition called paraesthesia), altered taste or dysgeusia, insomnia, dry mouth, constipation, dizziness, and metabolic acidosis (a condition characterized by the production of too much acid or when the kidneys fail to remove enough acid from the body).
Despite the inclination to presently overlook the drug’s serious side-effects for the benefit of the millions of obese individuals who, hopefully, will not be harmed by the drug, those who have already been made to suffer are encouraged to report their individual cases and seek the help of a highly-qualified lawyer who will help them file a Qsymia lawsuit for the possibility of receiving the compensation that will enable them to seek and undergo the necessary medical treatment.